457 related articles for article (PubMed ID: 31842339)
1. The Microbiota and Cancer Cachexia.
Herremans KM; Riner AN; Cameron ME; Trevino JG
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31842339
[TBL] [Abstract][Full Text] [Related]
2. Understanding the gut microbiota in cancer cachexia.
Rocha IM; Fonseca DC; Torrinhas RSM; Waitzberg DL
Curr Opin Clin Nutr Metab Care; 2023 Sep; 26(5):482-489. PubMed ID: 37389459
[TBL] [Abstract][Full Text] [Related]
3. Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options.
Panebianco C; Villani A; Potenza A; Favaro E; Finocchiaro C; Perri F; Pazienza V
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768173
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota and metabolic aspects of cancer cachexia.
Ziemons J; Smidt ML; Damink SO; Rensen SS
Best Pract Res Clin Endocrinol Metab; 2021 May; 35(3):101508. PubMed ID: 33648847
[TBL] [Abstract][Full Text] [Related]
5. Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study.
de Clercq NC; van den Ende T; Prodan A; Hemke R; Davids M; Pedersen HK; Nielsen HB; Groen AK; de Vos WM; van Laarhoven HWM; Nieuwdorp M
Clin Cancer Res; 2021 Jul; 27(13):3784-3792. PubMed ID: 33883174
[TBL] [Abstract][Full Text] [Related]
6. From Mouth to Muscle: Exploring the Potential Relationship between the Oral Microbiome and Cancer-Related Cachexia.
Raman SR; Liu C; Herremans KM; Riner AN; Vudatha V; Freudenberger DC; McKinley KL; Triplett EW; Trevino JG
Microorganisms; 2022 Nov; 10(11):. PubMed ID: 36422360
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Potential of the Gut Microbiota in the Prevention and Treatment of Sepsis.
Haak BW; Prescott HC; Wiersinga WJ
Front Immunol; 2018; 9():2042. PubMed ID: 30250472
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Gut Microbiota to Treat Cachexia.
Genton L; Mareschal J; Charretier Y; Lazarevic V; Bindels LB; Schrenzel J
Front Cell Infect Microbiol; 2019; 9():305. PubMed ID: 31572686
[TBL] [Abstract][Full Text] [Related]
9. Possibilities of therapeutic manipulation of the gut microbiota.
Drastich P; Bajer L; Kverka M
Vnitr Lek; 2018; 64(6):665-671. PubMed ID: 30223665
[TBL] [Abstract][Full Text] [Related]
10. Muscle wasting: the gut microbiota as a new therapeutic target?
Bindels LB; Delzenne NM
Int J Biochem Cell Biol; 2013 Oct; 45(10):2186-90. PubMed ID: 23831839
[TBL] [Abstract][Full Text] [Related]
11. The metabolite butyrate produced by gut microbiota inhibits cachexia-associated skeletal muscle atrophy by regulating intestinal barrier function and macrophage polarization.
Liu H; Xi Q; Tan S; Qu Y; Meng Q; Zhang Y; Cheng Y; Wu G
Int Immunopharmacol; 2023 Nov; 124(Pt B):111001. PubMed ID: 37804658
[TBL] [Abstract][Full Text] [Related]
12. Role of Gut Microbiota in Type 2 Diabetes Mellitus and Its Complications: Novel Insights and Potential Intervention Strategies.
Woldeamlak B; Yirdaw K; Biadgo B
Korean J Gastroenterol; 2019 Dec; 74(6):314-320. PubMed ID: 31870137
[TBL] [Abstract][Full Text] [Related]
13. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
Ferrere G; Wrzosek L; Cailleux F; Turpin W; Puchois V; Spatz M; Ciocan D; Rainteau D; Humbert L; Hugot C; Gaudin F; Noordine ML; Robert V; Berrebi D; Thomas M; Naveau S; Perlemuter G; Cassard AM
J Hepatol; 2017 Apr; 66(4):806-815. PubMed ID: 27890791
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
15. Psoriasis: Interplay between dysbiosis and host immune system.
Kapoor B; Gulati M; Rani P; Gupta R
Autoimmun Rev; 2022 Nov; 21(11):103169. PubMed ID: 35964945
[TBL] [Abstract][Full Text] [Related]
16. [Intestinal microbiota - a vital "organ" with manifold functions].
Konturek P; Konturek K; Zopf Y; Harsch IA
MMW Fortschr Med; 2020 Mar; 162(Suppl 4):9-14. PubMed ID: 32189316
[TBL] [Abstract][Full Text] [Related]
17. Dysbiosis in Functional Bowel Disorders.
Enck P; Mazurak N
Ann Nutr Metab; 2018; 72(4):296-306. PubMed ID: 29694952
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.
Metta V; Leta V; Mrudula KR; Prashanth LK; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
J Neurol; 2022 Mar; 269(3):1154-1163. PubMed ID: 33881598
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota and inflammatory bowel disease: so far so gut!
Holleran G; Lopetuso LR; Ianiro G; Pecere S; Pizzoferrato M; Petito V; Graziani C; McNAMARA D; Gasbarrini A; Scaldaferri F
Minerva Gastroenterol Dietol; 2017 Dec; 63(4):373-384. PubMed ID: 28293937
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT).
Lee P; Yacyshyn BR; Yacyshyn MB
Diabetes Obes Metab; 2019 Mar; 21(3):479-490. PubMed ID: 30328245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
